This article is available to subscribers. Subscribe now. Already have an account? Sign in
PerspectiveStatistics in Medicine
I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development?List of authors.
The I-SPY 2 breast cancer trials assess activity of new agents by adaptive randomization, applying criteria for success on a surrogate end point to predict success in confirmatory trials. Innovative designs may speed progress and eliminate waste in drug development.
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Print Subscriber? Activate your online access.